In May 2020, PixCell Medical collaborated with Interreg Germany-Denmark’s Changing Cancer Care (CCC) initiative, to enable home-based blood testing to support treatment of cancer patients in homecare settings. The goal? Limiting immunocompromised patients’ exposure to contagion in a hospital.

Cancer patients in Denmark have been trained to use the HemoScreen to perform the 5-part Complete Blood Count (CBC) test required to manage their treatments and support clinical decision-making. Within just 5 minutes and with one finger prick of blood, HemoScreen provides results for 20 standard CBC parameters. Using HemoScreen, patients can safely and routinely test their blood levels at home, without having to waste time and precious energy in oncology wards.

“I find it really exciting [to be able to take my own blood sample at home] and I like to take the time to study the blood samples to see how they may have changed from before,” said Lene Bergo, a breast cancer patient who uses PixCell’s HemoScreen to take her own blood samples. “Taking a blood sample by yourself is easy!”

Watch this video to learn more about this partnership and the impact it has on the lives of cancer patients in Denmark.

Disclaimer: The HemoScreen is not approved for home-use. This clinical trial collaboration is being performed under local ethical approval.

“We found the PixCell hematology analyzer simple to operate, extremely portable and reliable. Our non-technical staff quickly and easily learned how to perform the testing.

The small size of the machine and ability to test either finger stick capillary blood or drops of blood from collection tubes allowed us to use this machine in a variety of settings.

I appreciated the use of image analysis to accurately deliver complete blood counts with 5 part differential testing in just a few minutes. This versatile analyzer will be extremely helpful in providing accurate and reliable CBC with differential results in settings (i.e outpatient, clinic, bedside) where immediate feedback plays a significant role in patient outcomes.

This includes, in part, pediatric and adult patients with de novo acute leukemia, marked neutropenia, or red blood cell and platelet disorders that result in significant and life threatening bleeding”

Prof. Carla Wilson MD, PhD

“Overcrowding and prolonged wait times have been linked to adverse clinical outcomes and decreased patient satisfaction.

While no one factor can be identified as the root cause of this issue, decrease in delays between sample collection and test results can provide health care professionals with the opportunity to arrive at faster care management decisions, resulting in increased patient throughput and decreasing average wait times.

We have thoroughly evaluated the HemoScreen performance and usability in different settings and found it extremely easy-to-use and highly accurate thus a perfect fit for urgent care settings and primary care.”

Prof. Anders Larsson